Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcSé HER2 zanidatamab in HER2-altered solid tumors
2025-522169-31-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanidatamab in endometrial cancer (EC), colorectal cancer (CRC), head and neck cancer (HNC) and 2 more, sponsored by Unicancer. Planned start Oct 2025; status: authorised.
02
Drugs
zanidatamab
03
Conditions
endometrial cancer (EC)colorectal cancer (CRC)head and neck cancer (HNC)non-small cell lung cancer (NSCLC)Bone and soft tissue sarcoma
Beyond the preview
Go deeper on 2025-522169-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522169-31-00.